Name: 2nd Annual MarketsandMarkets Real-World Evidence and Market Access Conference
Start: 2024-10-14
End: 2024-10-15
Location: Dorint Thermenhotel- Gesundheitsresort Freiburg

WHAT TO EXPECT

Updates on European regulatory frameworks governing real-world evidence (RWE) and their impact on market access strategies.
Ensuring the reliability, validity, and relevance of RWE in the context of market access.
Effective collaboration strategies between industry stakeholders and payers to enhance market access outcomes.
Strategies for pricing and reimbursement that align with evidence-based market access approaches.
The impact of patient-reported outcomes on demonstrating product value and effectiveness.
The role of health economics in demonstrating the economic value of healthcare interventions.

Learn about the recent trends and advancements in Real-World Evidence Generation
Engage in meaningful discussion with the most prominent industry experts and decision makers from pharmaceutical and biopharmaceutical companies who will address most critical challenges in real-world data and real-world evidence space.
Opportunity to network and exchange scientific knowledge with expert speakers from leading pharmaceutical companies, global regulators and solution providers

From pharmaceutical and Biopharmaceutical companies

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists within the following departments-

Real-World Evidence
Real-World Data
Data Analytics
Health Economics & Outcomes Research- HEOR
Market Access/Value Access
Policy
Clinical Development & research
Clinical trial
Centre for Observational and Real-World Evidence
Epidemiology
Oncology-RWE
Pricing and Reimbursement
Medical Affairs
Pharmacovigilance
Life Science Analytics
Big data
Data Science
Bio-Statistics
Consumer Healthcare

Other

Payers, Regulators, Research Institutes, and Innovation Centre

CONFERENCE AGENDA

Registration	08:15 - 09:00
Welcome note by MarketsandMarkets	09:00 - 09:05
Opening remarks by the Chairperson Sandeep Kiri, Global Head of Health Economic Evidence- PPRWE, UCB	09:05 - 09:10
Data Quality and Standardization
Use of patient reported outcomes in real-world evidence: Prurigo Nodularis as an example. Donia Bahloul, Global and US HEOR Business Partner, Global Health Economics & Value Assessment, Sanofi	09:10 - 09:40
RWE in the EU Joint Clinical Assessment- Opportunities and Challenges? Sandeep Kiri, Global Head of Health Economic Evidence- PPRWE, UCB	09:40 - 10:10
Electronic Health Record meets Evidence Ralf Patsch, Head of Real-World Data Business Germany, Cegedim	10:10 - 10:40
Morning Refreshments and Poster Presentation \| One-to-One Networking Meeting	10:40 - 11:30
RWE for Health Technology Assessment (HTA)
The Power of High-Quality Real-World Data in Oncology Maike Sauer, Head of Network & Commercial Partnerships, Flatiron Health	11:30 - 12:00
The Statistical Abyss that is RWE for HTA Martin Scott, Scientific Director, Numerus	12:00 - 12:30
Methodological considerations with the development and implementation of external control arms using routine electronic health records Lewis Carpenter, Director Real World Evidence, Arcturis Data	12:30 - 13:00
Lunch and Poster Presentation \| One-to-One Networking	13:00 - 14:00
Post-Marketing Surveillance and Phase IV Trials
Population adjusted RCTs – an option for long-term comparisons? Michael Happich, Sr Director HTA, International Markets, Eli Lilly and Company	14:00 - 14:30
Real-life demonstrations of AI in practice for Market Access & HEOR teams Thomas Gilboy, Owner- Market Access Digital Tools, Access Infinity	14:30 - 15:00
Panel Discussion- RWE in assessing long-term safety and effectiveness of interventions. Lewis Carpenter, Director Real World Evidence, Arcturis Data Alexandre Templier, Co-founder and President, Quinten Health Ralf Patsch, Head of Real-World Data Business Germany, Cegedim Martin Scott, Scientific Director, Numerus Donia Bahloul, Global and US HEOR Business Partner, Global Health Economics & Value Assessment, Sanofi	15:00 - 15:40
Evening Refreshments and Poster Presentation \| One-to-One Networking	15:40 - 16:25
Patient Recruitment and Retention
Bridging the chasm between successful clinical trials and long-term Benefit/Risk and medico-economic impact demonstration: towards mutualized disease-centric cohort simulators Alexandre Templier, Co-founder and President, Quinten Health	16:25 - 16:55
Real world influence of real world evidence for policy decision making at NICE’ Vandana Ayyar-Gupta, Scientific Adviser, Data & Analytics, National Institute for Health, and Care Excellence	16:55 - 17:25
Closing Remarks from the Chairperson Sandeep Kiri, Global Head of Health Economic Evidence- PPRWE, UCB	17:25 - 17:25

Registration	08:15 - 08:50
Welcome note by MarketsandMarkets	08:50 - 09:05
Opening remarks by the Chairperson Gustavo Olivera, HEOR (Health Economics & Outcomes Research) Senior Expert, Sanofi	09:05 - 09:10
Patient-Centric Market Access
Innovation in Real-World Data/Real-World Evidence: Sabrina de Souza, Associate Director, Real World Data Scientist (CMS, PRWE), Merck	09:10 - 09:40
Overcoming Challenges in Real-World Evidence through Federated Learning José-Tomás Prieto, AI programs Lead, Apheris Jeffrey Brown, PhD, Chief Scientific Officer, TriNetX	09:40 - 10:10
Comparative retrospective RWE database studies: why and how to do them Thomas Wilke, Senior Scientist, GIPAM Health	10:10 - 10:45
Morning Refreshments and Poster Presentation \| One-to-One Networking	10:45 - 11:30
RWE in Market Access for Rare Diseases & Other Medical Conditions
Evidence Appraisal and Public Health decision-making in a post-pandemic era: insights from the world of vaccines. Gustavo Olivera, HEOR (Health Economics & Outcomes Research) Senior Expert, Sanofi	11:30 - 12:00
RWD in immunology and neurology Laurent Laffineur, Head of Business Development, Cascador Health	12:00 - 12:30
Joint Clinical Assessment: Getting there and moving from there Remon Helmy, Associate Director, Health Economics & Outcomes Research (HEOR), Alexion, AstraZeneca Rare Disease	12:40 - 13:00
Closing remarks by the chairperson Gustavo Olivera, HEOR (Health Economics & Outcomes Research) Senior Expert, Sanofi	13:00 - 13:15
Lunch and Poster Presentation \| One-to-One Networking	13:15 - 13:15